Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Archive for the 'paclitaxel' Category

paclitaxel news feed.

October 31st, 2008. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors

The RD determined was pemetrexed 500 mg/m2 (d8) and paclitaxel 90 mg/m2 (d1 and d8), q21d. The combination was well tolerated and showed efficacy in thyroid carcinoma and mesothelioma.
Posted in Chemotherapy, Full Archive, Pemetrexed (Alimta), Treatment, paclitaxel | No Comments »

October 2nd, 2008. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Pemetrexed, a multitargeted antifolate agent, has shown clear activity in several tumors, including mesothelioma and NSCLC. In a phase III trial, second-line treatment with pemetrexed demonstrated overall survival comparable to docetaxel, with a more manageable toxicity profile.
Posted in Bevacizumab (Avastatin), Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Docetaxel (Taxotere), Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Treatment, Type of Assessment:, paclitaxel | No Comments »

June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance

The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, melphalan, paclitaxel | No Comments »

May 27th, 2008. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Conclusion: Based on the data reviewed, > 70% of patients who might otherwise have been eligible for standard advanced NSCLC trials were not candidates for ECOG 4599. Outcome with respect to this study must be interpreted in the context of eligibility restrictions.
Posted in Bevacizumab (Avastatin), Carboplatin, Chemotherapy, Full Archive, Treatment, Type of Assessment:, paclitaxel | No Comments »

August 24th, 2007. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel

Conclusion: The combination of radiotherapy and intraperitoneal paclitaxel seems suitable in palliative settings primarily aimed at improving the quality of life.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Radiation, Treatment, Type of Assessment:, Type of Mesothelioma:, paclitaxel | No Comments »
Goldberg, Persky & White, P.C. Mesothelioma Lawyers